Zealand Pharma (ZLDP.F) Stock Overview

A biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. More details

ZLDP.F fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	3/6
Financial Health	5/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (3.2x) is below the US market (18.6x)

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 75% per year for the next 3 years

High level of non-cash earnings

Volatile share price over the past 3 months compared to the US market

ZLDP.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Zealand Pharma A/S Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zealand Pharma
Historical stock prices
Current Share Price	DKK 44.70
52 Week High	DKK 83.12
52 Week Low	DKK 35.93
Beta	0.59
1 Month Change	-17.22%
3 Month Change	9.05%
1 Year Change	-39.70%
3 Year Change	10.10%
5 Year Change	41.01%
Change since IPO	256.18%

Recent updates

Shareholder Returns

	ZLDP.F	US Biotechs	US Market
7D	-8.8%	-1.9%	-4.1%
1Y	-39.7%	23.6%	20.6%

Return vs Industry: ZLDP.F underperformed the US Biotechs industry which returned 23.6% over the past year.

Return vs Market: ZLDP.F underperformed the US Market which returned 20.6% over the past year.

Price Volatility

Is ZLDP.F's price volatile compared to industry and market?
ZLDP.F volatility
ZLDP.F Average Weekly Movement	14.9%
Biotechs Industry Average Movement	10.6%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ZLDP.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ZLDP.F's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
1997	544	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
ZLDP.F fundamental statistics
Market cap	US$3.20b
Earnings (TTM)	US$990.91m
Revenue (TTM)	US$1.43b

3.2x

P/E Ratio

2.2x

P/S Ratio

Is ZLDP.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ZLDP.F income statement (TTM)
Revenue	DKK 9.24b
Cost of Revenue	DKK 816.00k
Gross Profit	DKK 9.24b
Other Expenses	DKK 2.84b
Earnings	DKK 6.40b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 13, 2026

Earnings per share (EPS)	91.06
Gross Margin	99.99%
Net Profit Margin	69.21%
Debt/Equity Ratio	2.1%

How did ZLDP.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/11 01:11
End of Day Share Price	2026/06/11 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zealand Pharma A/S is covered by 34 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Yihan Li	Barclays
Kerry Holford	Berenberg
Laura Hindley	Berenberg

Zealand Pharma (ZLDP.F) Stock Overview

Rewards

Risk Analysis

Zealand Pharma A/S Competitors

TG Therapeutics

Krystal Biotech

Kiniksa Pharmaceuticals International

Catalyst Pharmaceuticals

Price History & Performance

Recent News & Updates

Zealand Pharma A/S and Roche to Advance Petrelintide, Amylin Analog, to Phase 3 Trials for Chronic Weight Management

Zealand Pharma Announces Boehringer Ingelheim's Survodutide Achieves Significant Weight Loss and Metabolic Improvement in Phase 3 Trial

Zealand Pharma A/S Announces the Appointment of Eric Rojas as Head of Investor Relations, Effective April 15, 2026

Zealand Pharma A/S Approves Management Changes

Zealand Pharma Announces Positive Phase 2 Results for Petrelintide

Zealand Pharma A/S, Annual General Meeting, Mar 26, 2026

Recent updates

Zealand Pharma A/S and Roche to Advance Petrelintide, Amylin Analog, to Phase 3 Trials for Chronic Weight Management

Zealand Pharma Announces Boehringer Ingelheim's Survodutide Achieves Significant Weight Loss and Metabolic Improvement in Phase 3 Trial

Zealand Pharma A/S Announces the Appointment of Eric Rojas as Head of Investor Relations, Effective April 15, 2026

Zealand Pharma A/S Approves Management Changes

Zealand Pharma Announces Positive Phase 2 Results for Petrelintide

Zealand Pharma A/S, Annual General Meeting, Mar 26, 2026

Zealand Pharma A/S Announces Positive Phase 1a Topline Results with Kv1.3 Channel Backer ZP9830

Zealand Pharma A/S to Report Q1, 2026 Results on May 07, 2026

Zealand Pharma A/S(CPSE:ZEAL) dropped from FTSE All-World Index (USD)

Zealand Pharma A/S Announces Positive Topline Clinical Results from Part 2 of a Phase 1b Multiple Ascending Dose (MAD) Trial

Zealand Pharma A/S Submits Marketing Authorization Application to the European Medicines Agency for Glepaglutide in Short Bowel Syndrome

Zealand Pharma A/S to Report Q4, 2025 Results on Feb 19, 2026

Zealand Pharma Announces First Participant Enrolled in Phase 2b ZUPREME-2 Trial of Petrelintide in People with Overweight or Obesity and Type 2 Diabetes

Zealand Pharma A/S Appoints Utpal Singh as Chief Scientific Officer

Zealand Pharma A/S, Annual General Meeting, Mar 27, 2025

Zealand Pharma A/S Announces U.S. Food and Drug Administration Issues Complete Response Letter for the New Drug Application for the Treatment of Short Bowel Syndrome

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil